BPG is committed to discovery and dissemination of knowledge
Retrospective Study Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123385
Published online Nov 15, 2026. doi: 10.4251/wjgo.123385
Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma
Fei Ma, Dan-Jun Song, Fei Cao, Wei-Yuan Hao, Jia-Ping Zheng, Department of Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310022, Zhejiang Province, China
Fei Ma, Jia-Ping Zheng, Graduate Training Base of Wenzhou Medical University, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China
Li-Yun Zheng, Zhong-Wei Zhao, Department of Radiology, Zhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, China
Jun-Qi Qiu, Department of Gastroenterology, Pingyang County People’s Hospital Affiliated to Wenzhou Medical University, Wenzhou 325400, Zhejiang Province, China
Dong Lu, Department of Intervention, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei 230001, Anhui Province, China
Dong Lu, Department of Intervention, The Second Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China
ORCID number: Fei Ma (0009-0002-9246-3039); Wei-Yuan Hao (0000-0001-5203-9714); Jia-Ping Zheng (0000-0003-0367-9250).
Co-first authors: Fei Ma and Li-Yun Zheng.
Co-corresponding authors: Dong Lu and Jia-Ping Zheng.
Author contributions: Zheng JP conceptualized and designed the study; Lu D contributed to refining the study design, interpreting the findings, reviewing the relevant literature, and preparing the manuscript; Song DJ, Zhao ZW, Cao F, Hao WY, and Qiu JQ collected, accessed, and verified the study data; Ma F and Zheng LY contributed to the statistical evaluation and manuscript preparation; and all authors read and approved the final manuscript. Ma F was primarily responsible for the statistical analyses, evaluation of the study results, and preparation of the initial manuscript. Zheng LY contributed to interpretation of the analyzed data and manuscript revision. Both authors made comparable contributions to data interpretation, evaluation of the results, and manuscript preparation, supporting their designation as co-first authors. As co-corresponding authors, Zheng JP and Lu D made complementary contributions to the study. Zheng JP initiated the study, defined the study objectives, eligibility criteria, and data collection plan, supervised the research process, coordinated study implementation, and critically revised the manuscript. He established the overall analytical framework for comparing the real-world effectiveness of regorafenib monotherapy and regorafenib combined with programmed cell death-1 inhibitors as second-line treatment for unresectable hepatocellular carcinoma. Lu D contributed to refining the study design, interpreting the findings based on existing evidence, reviewing the literature, and preparing and revising the manuscript. Lu D also led the interpretation and discussion of subgroup findings in patients with prior first-line immune checkpoint inhibitor exposure. Their collaboration and complementary expertise were essential to the completion of the study and manuscript preparation, supporting their designation as co-corresponding authors.
AI contribution statement: Portions of this manuscript were edited using AI tools solely for language refinement. The authors carefully reviewed and verified all AI-assisted outputs and take full responsibility for the scientific content of the manuscript.
Institutional review board statement: This study was approved by the Institutional Ethics Committee of Zhejiang Cancer Hospital [approval No. IRB-2026-762 (IIT)].
Informed consent statement: The requirement for written informed consent was waived by the Institutional Ethics Committee of Zhejiang Cancer Hospital due to the retrospective nature of the study.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
Data sharing statement: No additional data are available.
Corresponding author: Jia-Ping Zheng, MD, PhD, Professor, Department of Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Banshan East Road, Hangzhou 310022, Zhejiang Province, China. zhengjp@zjcc.org.cn
Received: May 18, 2026
Revised: June 29, 2026
Accepted: July 16, 2026
Published online: November 15, 2026
Processing time: 172 Days and 18.8 Hours

Abstract
BACKGROUND

Sorafenib and lenvatinib remain the standard first-line therapies for unresectable hepatocellular carcinoma (HCC); however, disease progression is nearly universal. Regorafenib has become a standard second-line agent based on the RESORCE trial. Immune checkpoint inhibitor (ICI), particularly programmed cell death-1 (PD-1) inhibitors, have further reshaped the therapeutic landscape. Preclinical studies have demonstrated that regorafenib may modulate the tumor immune microenvironment, thereby enhancing antitumor immunity. Nevertheless, robust real-world evidence evaluating the efficacy of regorafenib combined with PD-1 inhibitors after first-line failure remains limited.

AIM

To compare the clinical efficacy of regorafenib plus PD1 inhibitor vs monotherapy as a second-line treatment for patients with unresectable HCC.

METHODS

This study analyzed 140 advanced HCC patients who experienced disease progression after first-line therapy between February 2019 and August 2024. Patients were divided into two cohorts, the regorafenib plus PD1 inhibitor group [regorafenib plus PD1 inhibitor (RP) group, n = 101] and the regorafenib monotherapy group [regorafenib monotherapy (R) group, n = 39]. Clinical outcomes were evaluated using objective response rate, disease control rate (DCR), progression-free survival, and overall survival (OS). Subgroup analyses and multivariate Cox regression analysis were performed to identify prognostic factors.

RESULTS

The RP group achieved a higher DCR, with better control of both intrahepatic and extrahepatic lesions than the R group. Median PFS (5.4 months vs 2.7 months, P = 0.003) and OS (54.8 months vs 25.3 months, P = 0.041) were longer in the RP group. Patients with prior ICI exposure achieved longer OS with RP therapy (P = 0.006), whereas no significant OS difference was observed in ICI-naive patients. First-line treatment type (lenvatinib vs sorafenib) did not affect second-line outcomes. Multivariable analysis identified second-line PD-1 inhibitor therapy as an independent predictor of PFS, whereas no independent predictors of OS were identified.

CONCLUSION

For patients with unresectable HCC who fail first-line treatment, the combination of regorafenib and PD-1 inhibitors confers better survival benefits and disease control than regorafenib monotherapy.

Key Words: Unresectable hepatocellular carcinoma; Regorafenib; Programmed cell death-1 inhibitor; Second-line treatment; Prognostic factors

Core Tip: This multicenter retrospective study provides real-world evidence supporting regorafenib plus programmed cell death-1 (PD-1) inhibitors as second-line therapy for unresectable hepatocellular carcinoma after first-line treatment failure. Combination therapy improved disease control and prolonged progression-free and overall survival. Notably, survival benefit was mainly observed in patients with prior immune checkpoint inhibitor exposure, whereas first-line targeted therapy (lenvatinib or sorafenib) did not influence second-line outcomes. Second-line PD-1 inhibitor therapy independently predicted progression-free survival.



INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally, ranking sixth in terms of global incidence and third in cancer-related mortality[1]. Similarly, HCC is also one of the most prevalent cancers in China[2]. Due to the insidious nature of early clinical symptoms of HCC, most patients are diagnosed at an advanced stage and thus lose the opportunity for radical surgical resection[3]. For unresectable HCC, the main therapeutic strategies include local therapy, systemic anti-tumor therapy, conversion therapy, and supportive care[4]. In recent years, significant advances have been made in systemic therapy. First-line tyrosine kinase inhibitors (TKIs), such as sorafenib and lenvatinib, have been validated to confer significant survival benefits in multiple clinical trials[5]. Moreover, the phase III IMbrave150 trial demonstrated that atezolizumab combined with bevacizumab improves overall survival (OS) in patients with unresectable HCC[6]. However, some patients experience disease progression or intolerable toxicity, requiring second-line or subsequent treatment[7].

Regorafenib was the first agent approved by the United States Food and Drug Administration for second-line treatment of patients with advanced HCC based on the results of RESORCE trial[8,9]. Previous evidence has revealed that regorafenib can inhibit vascular endothelial growth factor receptor (VEGFR), modulate the JAK1/2-STAT1 and MAPK pathways, and downregulate programmed cell death ligand-1 (PD-L1) expression in HCC[10]. Additionally, it can normalize tumor vasculature and promote CD8+ T cell infiltration, thereby potentiating the antitumor efficacy of programmed cell death-1 (PD-1) antibodies[11]. These effects suggest that the combination of regorafenib and PD-1 inhibitors may further improve the treatment efficacy. A real-world study has demonstrated that regorafenib combined with PD-1 inhibitors as a second-line therapy could prolongs the median progression-free survival (PFS) compared with the regorafenib monotherapy (11.50 months vs 5.13 months) in patients with unresectable HCC[12]. In addition, this study further explored the prognostic differences in the second-line therapy among patients who received lenvatinib or sorafenib as first-line therapy, and assessed whether different first-line targeted treatments influenced the efficacy of second-line regorafenib combined with PD-1 inhibitors or monotherapy. Herein, based on multicenter retrospective data, this study evaluated the clinical efficacy of the combined therapeutic regimen for unresectable HCC and identified relevant prognostic factors. Subgroup analyses were further performed to assess the prognostic impacts of first-line immune checkpoint inhibitor (ICI) exposure and different first-line TKI regimens (lenvatinib vs sorafenib).

MATERIALS AND METHODS
Study design and patients

This multicenter retrospective study included 181 patients with HCC who received second-line regorafenib-based therapy after developing disease progression or experiencing intolerable toxicity to prior first-line treatment (e.g., sorafenib or lenvatinib). Patients were treated at four institutions: Zhejiang Cancer Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of University of Science and Technology of China, and The People’s Hospital of Pingyang, between February 2019 and August 2024. This retrospective multicenter study was approved by medical ethics committee of Zhejiang Cancer Hospital [approval No. IRB-2026-762 (IIT)] and other participating centers. It adhered to the Helsinki Declaration’s ethical guidelines, exempting patients from informed consent.

The inclusion criteria were as follows: (1) Age ≥ 18 years; (2) Clinically or pathologically confirmed diagnosis of HCC; (3) China Liver Cancer (CNLC) stage II or III; and (4) Receipt of regorafenib monotherapy or regorafenib combined with a PD1 inhibitor after first-line treatment failure. Patients were excluded from the study if they met any of the following exclusion criteria: (1) Absence of evaluable efficacy data; (2) Missing essential baseline clinical information; or (3) Presence of additional malignancies other than primary HCC. Figure 1 outlines the patient inclusion and exclusion process.

Figure 1
Figure 1 Flow diagram of the participants analyzed. HCC: Hepatocellular carcinoma; PD-1: Programmed cell death-1.
Data collection

Baseline data were collected within one week before the initiation of second-line treatment. Recorded parameters included (1) Age; (2) Sex; (3) History of comorbidities (hypertension, diabetes mellitus); (4) Hepatitis B/C virus infection status; (5) Eastern Cooperative Oncology Group performance status; (6) Child-Pugh class; (7) CNLC stage; (8) Tumor size; (9) Portal vein tumor thrombus; (10) First-line treatment regimen; (11) Prior exposure to ICIs during first-line therapy; and (12) Initial daily dose of regorafenib. Laboratory examinations included: (1) Complete blood count; (2) Liver function tests; (3) Coagulation function tests; and (4) Serum tumor biomarkers.

Treatment methods

In the second-line therapy, patients received oral regorafenib at a daily dose of 40-160 mg (adjusted based on tolerability) for 21 consecutive days followed by a 7-day treatment-free interval, constituting a 28-day cycle. Patients in the combination group received concurrent intravenous PD-1 inhibitors with the following fixed dosing regimens: Sintilimab 200 mg every 3 weeks, tislelizumab 200 mg every 3 weeks, camrelizumab 200 mg every 2 weeks, toripalimab 240 mg every 3 weeks, and nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks. Dose modifications and the application of additional locoregional therapies were determined by the institutional multidisciplinary team.

Efficacy assessment

The primary endpoint was PFS, and the secondary endpoints were OS, objective response rate (ORR), and disease control rate (DCR). PFS was measured from initiation of second-line treatment to disease progression or death from any cause, whichever occurred first. OS was measured from initiation of second-line treatment to death from any cause. ORR and DCR were defined as the proportions of patients achieving complete response (CR) or partial response (PR), and CR, PR, or stable disease (SD), respectively.

Treatment efficacy was assessed starting from the date of the first regorafenib administration. Tumor response was evaluated every 4-8 weeks using computed tomography or magnetic resonance imaging according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 until disease progression, treatment modification, treatment discontinuation, or death. All analyses were conducted based on data available at the final followup date (May 2025).

Statistical analysis

Categorical variables were presented as n (%) and were compared using the χ2 test or Fisher’s exact test. Continuous variables were expressed as median (interquartile range) or mean ± SD, according to data distribution, and were compared using the independentsamples t-test or Mann-Whitney U test.

OS and PFS were estimated with the Kaplan-Meier method, with betweengroup differences assessed using the Logrank test. Subgroup analyses were performed to explore prognostic variations stratified by different firstline regimens. Multivariable Cox proportionalhazards regression analysis was performed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Variables with a P < 0.10 in univariate analysis were entered into the multivariable Cox regression model. All statistical analyses were conducted in R (version 4.4.1). A twotailed P < 0.05 was considered statistically significant.

RESULTS
Patient baseline characteristics

In this study, we retrospectively identified 181 patients with advanced HCC who were treated with either regorafenib plus PD1 inhibitors or regorafenib monotherapy as secondline therapy at four participating institutions (Zhejiang Cancer Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of the University of Science and Technology of China, and The People’s Hospital of Pingyang) between February 2019 and August 2024. Of these, 140 patients met the inclusion criteria and were included in the final analysis: 101 in the regorafenib plus PD1 inhibitor (RP) group and 39 in the regorafenib monotherapy (R) group. No significant differences were observed in baseline characteristics between the two groups including demographic features, comorbidities, laboratory parameters and tumor characteristics (Table 1).

Table 1 Baseline characteristics of hepatocellular carcinoma patients treated with second-line regorafenib combination with programmed cell death-1 inhibitor or monotherapy, n (%).
Characteristics
Overall (n = 140)
R group (n = 39)
RP group (n = 101)
P value
Age0.811
    < 6599 (70.7)27 (69.2)72 (71.3)
    ≥ 6541 (29.3)12 (30.8)29 (28.7)
Gender0.652
    Female22 (15.7)7 (17.9)15 (14.9)
    Male118 (84.3)32 (82.1)86 (85.1)
Smoking0.839
    No95 (67.9)28 (71.8)67 (66.3)
    Yes39 (27.9)10 (25.6)29 (28.7)
    Unknown6 (4.3)1 (2.6)5 (5.0)
Drinking0.203
    No103 (73.6)26 (66.7)77 (76.2)
    Yes30 (21.4)12 (30.8)18 (17.8)
    Unknown7 (5.0)1 (2.6)6 (5.9)
Hepatitis B infection0.908
    No31 (22.1)8 (20.5)23 (22.8)
    Yes107 (76.4)31 (79.5)76 (75.2)
    Unknown2 (1.4)0 (0.0)2 (2.0)
Hepatitis C infection0.106
    No134 (95.7)38 (97.4)96 (95.0)
    Yes1 (0.7)1 (2.6)0 (0.0)
    Unknown5 (3.6)0 (0.0)5 (5.0)
Diabetes1.000
    No126 (90.0)36 (92.3)90 (89.1)
    Yes13 (9.3)3 (7.7)10 (9.9)
    Unknown1 (0.7)0 (0.0)1 (1.0)
Hypertension0.285
    No99 (70.7)25 (64.1)74 (73.3)
    Yes41 (29.3)14 (35.9)27 (26.7)
First-line ICI therapy0.224
    No53 (37.9)14 (35.9)39 (38.6)
    Yes72 (51.4)18 (46.2)54 (53.5)
    Unknown15 (10.7)7 (17.9)8 (7.9)
Tumor size0.323
    ≤ 5 cm46 (32.9)12 (30.8)34 (33.7)
    > 5 cm25 (17.9)10 (25.6)15 (14.9)
    Unknown69 (49.3)17 (43.6)52 (51.5)
CNLC0.715
    IIa + IIb50 (35.7)13 (33.3)37 (36.6)
    IIIa + IIIb90 (64.3)26 (66.7)64 (63.4)
Child-Pugh class0.714
    A74 (52.9)22 (56.4)52 (51.5)
    B21 (15.0)5 (12.8)16 (15.8)
    C2 (1.4)0 (0.0)2 (2.0)
    Unknown43 (30.7)12 (30.8)31 (30.7)
ECOG PS
    022 (15.7)5 (12.8)17 (16.8)0.908
    126 (18.6)9 (23.1)17 (16.8)
    29 (6.4)2 (5.1)7 (6.9)
    31 (0.7)0 (0.0)1 (1.0)
    Unknown82 (58.6)23 (59.0)59 (58.4)
Portal vein invasion tumor
    No66 (47.1)19 (48.7)47 (46.5)0.702
    Yes30 (21.4)9 (23.1)21 (20.8)
    Unknown44 (31.4)11 (28.2)33 (32.7)
Sites of metastasis
    Lung28 (45.2)9 (40.9)19 (47.5)
    Bone8 (12.9)3 (13.6)5 (12.5)
    Lymph node16 (25.8)6 (27.3)10 (25.0)
    Others10 (16.1)4 (18.2)6 (15.0)
Laboratory indicators, median [IQR]
    Platelet (× 109/L)151.00 [111.00, 217.25]152.00 [110.50, 178.00]151.00 [111.00, 222.00]0.577
    Hemoglobin (g/L)132.00 [107.00, 144.25]127.00 [114.50, 145.50]134.00 [107.00, 143.00]0.961
    ALT (IU/L)35.00 [23.00, 65.00]37.00 [23.00, 54.00]34.00 [23.00, 73.00]0.705
    AST (IU/L)41.50 [29.00, 82.75]46.00 [31.00, 104.00]41.00 [27.00, 74.00]0.265
    ALB (g/L)39.70 [36.12, 43.90]39.70 [36.45, 43.90]39.70 [36.20, 43.90]0.917
    TBIL (μmol/L)17.20 [11.15, 23.30]16.30 [13.20, 26.30]17.30 [10.65, 21.90]0.430
    DBIL (μmol/L)7.95 [5.18, 11.73]7.70 [5.00, 12.00]8.00 [5.20, 11.35]0.631
    PT (s)12.55 [11.80, 13.55]12.70 [11.90, 13.85]12.50 [11.70, 13.30]0.503
    INR1.03 [0.98, 1.11]1.04 [0.90, 1.10]1.02 [0.99, 1.13]0.465
    AFP (ng/mL)124.20 [7.60, 2000.00]101.10 [7.85, 1978.90]124.20 [7.20, 2403.61]0.970
Initial daily dose of regorafenib
    40 mg6 (4.3)1 (2.6)5 (5.0)0.057
    80 mg65 (46.4)13 (33.3)52 (51.5)
    120 mg12 (8.6)6 (15.4)6 (5.9)
    160 mg18 (12.9)5 (12.8)13 (12.9)
    Unknown39 (27.9)14 (35.9)25 (24.8)
Clinical efficacy

Treatment efficacy was evaluated according to RECIST 1.1 criteria for overall, intrahepatic, and extrahepatic lesions. No patient achieved a CR in the overall cohort. Among all patients, PR was observed in 2.85% of patients, SD in 57.86%, and PD in 39.29% in the overall assessment, resulting in an ORR of 2.85% and a DCR of 60.71% (Supplementary Table 1). For intrahepatic lesions, PR and SD rates were 2.85% and 73.57%, respectively, yielding an ORR of 2.85% and a DCR of 76.43%. For extrahepatic lesions, the corresponding rates were 2.14% for PR and 25.00% for SD, with an ORR of 2.14% and a DCR of 27.14%.

Patients were further stratified by treatment regimen (RP group vs R group) for lesion-based response analysis (Table 2). PR was observed only in the RP group, with rates of 3.96% for intrahepatic lesions and 5.77% for extrahepatic lesions, whereas no PR was recorded in the R group. For intrahepatic lesions, the RP group achieved a higher DCR than the R group (83.17% vs 58.97%, P = 0.007), accompanied by a lower PD rate (16.83% vs 38.46%, P = 0.007). A similar pattern was observed for extrahepatic lesions, with a higher DCR (59.62% vs 31.82%, P = 0.004) and a lower PD rate (40.38% vs 68.18%, P = 0.042) in the RP group. The recorded treatment-related adverse events are summarized in Supplementary Table 2.

Table 2 Best tumor responses as per Response Evaluation Criteria in Solid Tumors version 1.1 between the regorafenib combined with programmed cell death-1 inhibitor and regorafenib monotherapy groups, n (%).
Best Response
Overall response
Intrahepatic response
Extrahepatic response
RP group (n = 101)
R group (n = 39)
P value
RP group (n = 101)
R group (n = 39)
P value
RP group (n = 52)
R group (n = 22)
P value
CR0 (0.00)0 (0.00)1.0000 (0.00)0 (0.00)1.0000 (0.00)0 (0.00)1.000
PR4 (3.96)0 (0.00)0.5764 (3.96)0 (0.00)0.5753 (5.77)0 (0.00)0.550
SD66 (65.35)15 (38.46)0.00580 (79.21)23 (58.97)0.03128 (53.85)7 (31.82)0.126
PD31 (30.69)24 (61.54)0.00117 (16.83)15 (38.46)0.00721 (40.38)15 (68.18)0.042
ORR4 (3.96)0 (0.00)0.5764 (3.96)0 (0.00)0.5753 (5.77)0 (0.00)0.550
DCR70 (69.31)15 (38.46)0.00184 (83.17)23 (58.97)0.00731 (59.62)7 (31.82)0.0042
Survival analysis

For the entire cohort, the median OS was 54.6 months [95%CI: 25.3-not available (NA)], and the median PFS was 4.3 months (95%CI: 3.5-5.43) (Figure 2). In the RP group, median OS was 54.8 months (95%CI: 27.6-NA), compared with 25.3 months (95%CI: 15.0-NA) in the R group, representing a significant survival benefit for the combination therapy (HR = 0.506, 95%CI: 0.260-0.984, P = 0.041) (Figure 3A). Similarly, median PFS was 5.4 months (95%CI: 4.33-7.33) in the RP group vs 2.7 months (95%CI: 2.47-3.77) in the R group, with a longer PFS observed in the RP group (HR = 0.562, 95%CI: 0.380-0.831, P = 0.003) (Figure 3B).

Figure 2
Figure 2 Survival outcomes in the overall cohort. A: Overall survival; B: Progression-free survival.
Figure 3
Figure 3 Comparison of second-line treatment strategies. A: Overall survival; B: Progression-free survival in regorafenib combined with programmed cell death1 inhibitors group vs regorafenib monotherapy group. RP: Regorafenib combined with programmed cell death1 inhibitors; R: Regorafenib monotherapy.

Stratified analysis based on prior ICI exposure status revealed that OS exhibited no significant difference between the RP and R groups in patients without first-line ICI exposure (Figure 4A). In contrast, among patients with firstline ICI exposure, the OS was longer in the RP group than in the R group (P = 0.006) (Figure 4B). When stratified by the type of firstline targeted therapy, no significant difference in OS was observed between the two groups for patients receiving either lenvatinib or sorafenib (Figure 5). The findings on PFS were consistent with those on OS, demonstrating alignment between the two endpoints (Supplementary Figure 1). Among patients who received first-line treatment for HCC, lenvatinib did not improve PFS or OS compared with sorafenib (Supplementary Figure 2). Among patients with documented PD-1 inhibitor information, PFS and OS were comparable between those receiving camrelizumab and tislelizumab (Supplementary Figure 3).

Figure 4
Figure 4 Impact of prior first-line immune checkpoint inhibitor exposure on overall survival. A: Overall survival in patients without prior immune checkpoint inhibitor (ICI) combination; B: Overall survival in patients with prior ICI combination in the second-line regorafenib combined with programmed cell death1 inhibitors group vs regorafenib monotherapy group. RP: Regorafenib combined with programmed cell death1 inhibitors; R: Regorafenib monotherapy.
Figure 5
Figure 5 Influence of first-line tyrosine kinase inhibitor type on overall survival following second-line regorafenib-based therapy. A: Overall survival in regorafenib combined with programmed cell death1 inhibitors group; B: Overall survival in regorafenib monotherapy group, stratified by first-line lenvatinib vs sorafenib treatment.
Risk factor analysis for OS and PFS in all patients

For OS, univariate Cox regression analysis identified diabetes (P = 0.008), alanine aminotransferase (P = 0.052), alpha-fetoprotein (AFP) (P = 0.020), prior first-line ICI therapy (P = 0.083), Child-Pugh class (P = 0.024), and second-line PD-1 inhibitor therapy (P = 0.044) as candidate variables for multivariable analysis (Table 3). However, none remained independently associated with OS in the multivariable analysis (Table 3).

Table 3 Univariate and multivariate Cox analysis for overall survival.
CharacteristicsUnivariate analysis
Multivariate analysis
HR (95%CI)

P value
HR (95%CI)

P value
Gender (female vs male)1.551 (0.604-3.984)0.362
Age (< 65 vs ≥ 65 years)0.937 (0.428-2.054)0.871
Hepatitis B infection (no vs yes)0.910 (0.426-1.944)0.807
Hepatitis C infection (no vs yes)0.000 (0.000-inf)0.997
Diabetes (no vs yes)3.291 (1.362-7.952)0.0084.319 (0.783-23.801)0.093
Hypertension (no vs yes)1.267 (0.646-2.483)0.491
Smoking (no vs yes)1.042 (0.516-2.101)0.909
Drinking (no vs yes)1.120 (0.531-2.360)0.766
Tumor size (≤ 5 vs > 5 cm)1.626 (0.728-3.631)0.235
Child-Pugh class (A vs B + C)2.456 (1.127-5.352)0.0241.100 (0.349-53.465)0.871
ECOG PS (0 vs ≥ 1)1.002 (0.454-2.212)0.996
Portal vein invasion tumor (no vs yes)1.473 (0.688-3.153)0.319
CNLC (IIa + IIb vs IIIa + IIIb)1.347 (0.685-2.649)0.388
ALT (≤ 50 vs > 50 IU/L)2.044 (0.993-4.207)0.0522.221 (0.984-5.011)0.055
AST (≤ 40 vs > 40 IU/L)1.353 (0.656-2.793)0.413
ALB (< 35 vs ≥ 35 g/L)0.659 (0.313-1.389)0.273
TBIL (≤ 23 vs > 23 μmol/L)0.622 (0.238-1.622)0.331
AFP (< 400 vs ≥ 400 ng/mL)2.332 (1.140-4.769)0.0201.805 (0.743-4.383)0.192
INR (≤ 1.2 vs > 1.2)0.720 (0.098-5.294)0.747
First-line ICI therapy (no vs yes)1.891 (0.921-3.883)0.0832.159 (0.794-5.868)0.132
Initial daily dose of regorafenib (< 160 vs 160 mg)1.440 (0.594-3.491)0.419
Second-line PD-1 inhibitors therapy (no vs yes)0.505 (0.260-0.983)0.0440.502 (0.203-1.239)0.135

For PFS, univariate Cox regression analysis identified sex (P = 0.087), Child-Pugh class (P = 0.052), albumin (P = 0.068), AFP (P = 0.001), and second-line PD-1 inhibitor therapy (P = 0.004) as candidate variables for multivariable analysis (Table 4). In the multivariable analysis, AFP (HR = 1.749, 95%CI: 1.027-2.980, P = 0.040) and second-line PD-1 inhibitor therapy (HR = 0.549, 95%CI: 0.316-0.953, P = 0.033) remained independently associated with PFS (Table 4).

Table 4 Univariate and multivariate Cox analysis for progression-free survival.
CharacteristicsUnivariate analysis
Multivariate analysis
HR (95%CI)

P value
HR (95%CI)

P value
Gender (female vs male)1.552 (0.939-2.566)0.0871.800 (0.891, 3.635)0.101
Age (< 65 vs ≥ 65 years)0.909 (0.606-1.364)0.645
Hepatitis B infection (no vs yes)1.246 (0.793-1.957)0.340
Hepatitis C infection (no vs yes)0.923 (0.128-6.635)0.936
Diabetes (no vs yes)1.484 (0.794-2.772)0.216
Hypertension (no vs yes)0.927 (0.627-1.372)0.707
Smoking (no vs yes)0.748 (0.501-1.117)0.156
Drinking (no vs yes)0.762 (0.488-1.192)0.234
Tumor size (≤ 5 vs > 5 cm)1.021 (0.618-1.688)0.935
Child-Pugh class (A vs B + C)1.680 (0.995-2.837)0.0521.260 (0.658-2.414)0.485
ECOG PS (0 vs ≥ 1)1.171 (0.662-2.072)0.587
Portal vein invasion tumor (no vs yes)1.210 (0.762-1.919)0.419
CNLC (IIa + IIb vs IIIa + IIIb)1.139 (0.787-1.649)0.490
ALT (≤ 50 vs > 50 IU/L)1.037 (0.689-1.560)0.863
AST (≤ 40 vs > 40 IU/L)1.233 (0.840-1.810)0.284
ALB (< 35 vs ≥ 35 g/L)0.692 (0.466-1.027)0.0680.698 (0.425-1.176)0.177
TBIL (≤ 23 vs > 23 μmol/L)0.982 (0.641-1.505)0.934
AFP (< 400 vs ≥ 400 ng/mL)1.908 (1.285-2.834)0.0011.749 (1.027-2.980)0.040
INR (≤ 1.2 vs > 1.2)0.878 (0.380-2.026)0.760
First-line ICI therapy (no vs yes)1.344 (0.915-1.974)0.132
Initial daily dose of regorafenib (< 160 vs 160 mg)1.020 (0.593-1.755)0.942
Second-line PD-1 therapy (no vs yes)0.561 (0.379-0.830)0.0040.549 (0.31-0.953)0.033
DISCUSSION

This multicenter real-world study showed favorable clinical outcomes with regorafenib plus PD-1 inhibitors as second-line therapy for advanced HCC. The RP group achieved a DCR of 69.31% and a median PFS of 5.4 months, compared with 38.46% and 2.7 months in the R group. These findings suggest that the RP regimen offers tangible clinical benefits in advanced HCC. Previous preclinical studies have shown that regorafenib enhances PD1 blockade in a dosedependent manner in HCC models[13]. A multicenter study also found that regorafenib combined with sintilimab achieved better ORR (36.2% vs 16.4%), PFS (5.6 months vs 4.0 months) and OS (13.4 months vs 9.9 months) in advanced HCC compared with regorafenib monotherapy[14]. The combination therapy inhibits STAT3 activity and increases the expression of chemokine CXCL10, thereby enhancing the infiltration of tumor-penetrating and activated CD8+ T cells and improving their survival[13]. Collectively, these preclinical and clinical studies support the therapeutic rationale for regorafenib plus PD-1 inhibitors in advanced HCC. Our findings add to the growing clinical evidence supporting the use of the combination regimen as second-line therapy for advanced HCC.

Nevertheless, the ORR observed in the present study was lower than that reported in several prospective clinical trials. This discrepancy is more likely attributable to differences in response assessment and patient characteristics than to reduced therapeutic activity. Because retrospective imaging data were insufficient for standardized mRECIST- or iRECIST-based reassessment, tumor response was evaluated using RECIST version 1.1, which may underestimate treatment response by failing to capture treatment-related tumor necrosis and atypical immune-related response patterns[15]. In addition, all enrolled patients had experienced first-line treatment failure and generally had more advanced disease and greater clinical heterogeneity than those included in prospective trials. Therefore, direct comparisons of ORR across studies should be interpreted cautiously. Taken together, the observed improvement in DCR and PFS suggests that the clinical benefit of regorafenib plus PD-1 inhibitors may be primarily reflected by prolonged disease control rather than increased objective tumor response.

Moreover, the phase 3 non-inferiority trial by Kudo et al[16] reported that lenvatinib yielded non-inferior OS relative to sorafenib, which is consistent with our finding that survival outcomes were comparable between patients who had received lenvatinib or sorafenib as first-line treatment. Multivariable Cox analysis demonstrated that AFP ≥ 400 ng/mL and second-line PD-1 inhibitor therapy were independently associated with PFS. Elevated AFP has been widely recognized as a marker of aggressive tumor behavior and poor prognosis in HCC[17], in agreement with our findings. Second-line PD-1 inhibitor therapy also remained independently associated with prolonged PFS. Although no independent predictors of OS were identified after multivariable adjustment, the significant separation of the Kaplan-Meier survival curves suggests that combination therapy may still provide a survival benefit. Larger prospective studies are required to confirm this observation.

The survival benefit of continuing immunotherapy after progression on first-line ICI-based therapy remains controversial. Previous studies have suggested that for patients who experienced PD after first-line TKI plus PD-1 inhibitor combination therapy, continuous second-line immunotherapy does not confer additional survival benefits[18]. In contrast, Cheng et al[19] reported that the combination of an ICI with regorafenib was associated with improved OS in patients with advanced HCC following progression on first-line ICI-based therapy. In line with these latter findings, our subgroup analysis showed that patients with prior first-line ICI exposure achieved longer OS in the RP group than in the R group, whereas no significant difference was observed in those without prior ICI exposure. Notably, among patients treated with the two PD-1 inhibitors for which adequate data were available, camrelizumab and tislelizumab achieved comparable PFS and OS, consistent with the limited available evidence in advanced HCC[20]. These findings further suggest that the observed benefit may be attributable to continued PD-1 blockade rather than to a specific PD-1 inhibitor.

One plausible explanation for this finding is the immunologic priming effect induced by prior ICI therapy[21,22]. Initial exposure to ICIs may enhance tumor immunogenicity and sustain antitumor immune activation, thereby increasing responsiveness to subsequent therapy. Regorafenib may further synergize with continued PD-1 blockade, thereby contributing to improved clinical outcomes[23]. This hypothesis is supported by accumulating preclinical and translational evidence demonstrating that regorafenib exerts immunomodulatory effects beyond its antiangiogenic activity. By inhibiting multiple kinases involved in tumor-induced immunosuppression, including VEGFR, TIE2, and CSF1R, regorafenib has been shown to promote vascular normalization, reduce immunosuppressive myeloid cell populations, and facilitate CD8+ T-cell infiltration into the tumor microenvironment[24]. Continued PD-1 blockade may preserve T-cell effector function while preventing functional exhaustion, thereby enhancing antitumor immunity[25]. In addition, prior exposure to ICIs may expand the repertoire of tumor-specific T-cell clones through a process known as epitope spreading, potentially lowering the threshold for subsequent immune-mediated tumor elimination[26]. Collectively, these mechanisms may contribute to remodeling the tumor immune microenvironment toward a more inflamed phenotype and provide a biologically plausible explanation for the enhanced efficacy of regorafenib plus PD-1 inhibitors, particularly in patients previously primed with immunotherapy.

Although the proposed mechanisms are biologically plausible and supported by accumulating experimental evidence, they could not be directly evaluated in the present study because tumor microenvironment-related biomarkers, including baseline CD8+ T-cell density, PD-L1 expression, and immune-related gene signatures were unavailable. Consequently, whether immune remodeling contributed to the observed therapeutic effects could not be determined. Prospective biomarker-driven studies incorporating paired pre- and on-treatment tumor biopsies, serial peripheral blood sampling, and comprehensive immune profiling are warranted to validate these proposed mechanisms and identify predictive biomarkers to guide patient selection in combined therapy following prior ICI exposure.

This study has several limitations. As a retrospective observational study, selection bias and residual confounding cannot be completely excluded. Furthermore, the relatively small regorafenib monotherapy group may have reduced the precision of treatment effect estimates, particularly for OS. Incomplete information on portal vein tumor thrombus classification and regorafenib treatment exposure limited evaluation of their potential impact on clinical outcomes. Although comparable outcomes were found between camrelizumab and tislelizumab, information on specific PD-1 inhibitors and dosing schedules was incomplete for a proportion of patients. Therefore, treatment heterogeneity could not be fully evaluated, and these subgroup findings should be interpreted cautiously because of the limited subgroup sample size and incomplete treatment information. Tumor response was assessed using RECIST version 1.1 because retrospective imaging data were insufficient for standardized mRECIST- or iRECIST-based reassessment. Consequently, the antitumor activity and the combination regimen may have been underestimated. Finally, treatment-related adverse events were not systematically documented or graded according to Common Terminology Criteria for Adverse Events, limiting a comprehensive comparison of safety between the two groups. Accordingly, adequately powered prospective studies incorporating standardized treatment protocols, comprehensive assessment of treatment exposure and toxicity, integrated biomarker assessment, standardized mRECIST- or iRECIST-based response evaluation, and systematic safety monitoring are warranted to validate these findings and optimize patient selection for regorafenib plus PD-1 inhibitor therapy.

CONCLUSION

This multicenter real-world study confirms that regorafenib combined with PD-1 inhibitors is more effective than regorafenib monotherapy in the treatment of advanced unresectable HCC.

ACKNOWLEDGEMENTS

The authors thank all participating hospital staff for their efforts and all patients for their participation.

References
1.  Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-263.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 16785]  [Cited by in RCA: 18093]  [Article Influence: 9046.5]  [Reference Citation Analysis (55)]
2.  Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394:1145-1158.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 3067]  [Cited by in RCA: 2783]  [Article Influence: 397.6]  [Reference Citation Analysis (8)]
3.  Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450-1462.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 3748]  [Cited by in RCA: 3547]  [Article Influence: 506.7]  [Reference Citation Analysis (24)]
4.  Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, Liu L, Wen T, Kuang M, Zhang B, Tao K, Han G, Yan Z, Wang M, Liu R, Guo J, Zeng Z, Liang P, Ren Z, Hou J, Zhang Y, Liu X, Pan H, Bi F, Liang C, Chen M, Yan F, Xu H, Xie X, Ju S, Ji Y, Yun J, Li Z, Bai X, Cai D, Chen W, Chen Y, Chen Y, Cheng W, Cheng S, Dai Z, Dai C, Gao Q, Guo R, Guo W, Guo Y, Hua B, Huang X, Jiang H, Jia W, Li Q, Li T, Li X, Li X, Li Y, Li Y, Liang J, Liang X, Ling C, Liu H, Liu T, Lu S, Lv G, Mao Y, Meng Z, Peng T, Ren W, Shi G, Shi H, Shi M, Song T, Tan G, Wang J, Wang K, Wang L, Wang W, Wang X, Wang Z, Xiang B, Xia J, Xing B, Xu J, Xu J, Yang J, Yang X, Yang Y, Yang Y, Yao X, Yin Z, Yuan Z, Zeng Y, Zeng Y, Zhang B, Zhang L, Zhang S, Zhang T, Zhang Z, Zhao M, Zhao Y, Zheng H, Zhou L, Zhu J, Zhu K, Shi Y, Liu R, Zhang L, Xiao Y, Yang C, Wu Z, Ding Z, Zhu X, Tang Z, Huang X, Han H, Wu H, Chen M, Wang W, Li Q, Cai J, Shen F, Cai X, Qin S, Teng G, Fan J. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition). Liver Cancer. 2025;14:779-835.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 4]  [Cited by in RCA: 51]  [Article Influence: 51.0]  [Reference Citation Analysis (5)]
5.  Kuo HY, Khan KA, Kerbel RS. Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nat Rev Clin Oncol. 2024;21:468-482.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 96]  [Reference Citation Analysis (0)]
6.  Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894-1905.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6170]  [Cited by in RCA: 5990]  [Article Influence: 998.3]  [Reference Citation Analysis (15)]
7.  Song YG, Yoo JJ, Kim SG, Kim YS. Complications of immunotherapy in advanced hepatocellular carcinoma. J Liver Cancer. 2024;24:9-16.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 24]  [Reference Citation Analysis (0)]
8.  Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol. 2019;9:221-232.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 115]  [Cited by in RCA: 207]  [Article Influence: 29.6]  [Reference Citation Analysis (5)]
9.  Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 3029]  [Cited by in RCA: 2923]  [Article Influence: 324.8]  [Reference Citation Analysis (12)]
10.  Liu J, Tao H, Yuan T, Li J, Li J, Liang H, Huang Z, Zhang E. Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Front Immunol. 2022;13:992611.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 17]  [Cited by in RCA: 16]  [Article Influence: 4.0]  [Reference Citation Analysis (2)]
11.  Zhao J, Guo Y, Feng T, Rong D, Kong X, Huang T, Lopez-Lopez V, Yarmohammadi H, Sakamoto Y, Zhu D, Yao A, Xia Y. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol. 2023;14:2549-2558.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 9]  [Reference Citation Analysis (0)]
12.  Bi H, Pei J, Ma K, Zhang Y, Aprile G, Moris D, Méndez-Sánchez N, Samant H, Sun X, Xia F. Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice. J Gastrointest Oncol. 2024;15:368-376.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1]  [Cited by in RCA: 5]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
13.  Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020;8:e001435.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 129]  [Cited by in RCA: 128]  [Article Influence: 21.3]  [Reference Citation Analysis (1)]
14.  Huang J, Guo Y, Huang W, Hong X, Quan Y, Lin L, Zhou J, Liang L, Zhang Y, Zhou J, Cai M, Zhu K. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Hepatocell Carcinoma. 2022;9:157-170.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 4]  [Cited by in RCA: 46]  [Article Influence: 11.5]  [Reference Citation Analysis (1)]
15.  Zand KA, Kim TH, Mukherji R, Ismail M, El Homsi M, Imanzadeh A, Kamath A, Singh C, Yacoub JH. Review of systemic therapy in HCC with an approach to response assessment in clinical practice. Abdom Radiol (NY).  2026.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 1]  [Reference Citation Analysis (4)]
16.  Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-1173.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 4538]  [Cited by in RCA: 4392]  [Article Influence: 549.0]  [Reference Citation Analysis (19)]
17.  Jiang S, Wang Y, Fu X, Lou J, Gong B, Liu W, Li Y, Sun Y, Liu C, Song Z, Zhou G. Clinical significance of AFP and PIVKA-II for predicting prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol. 2025;17:17588359251386801.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 3]  [Reference Citation Analysis (0)]
18.  Ma W, Li Y, Lu Y, Liang Z, Yu H, Han J, Liu J, Wang W, Peng C, Cheng J. A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2025;12:2123-2137.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 10]  [Reference Citation Analysis (0)]
19.  Cheng Y, Wang JY, Lu Y, Xia YX, Zhao H, Wang Q, Zhu XL, Zu QQ, Li HK, Chen Z, Li XC; China Liver Cancer Study Group Young Investigators (CLEAP). Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study. Hepatobiliary Pancreat Dis Int. 2025;24:656-665.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
20.  Zou H, Ge Y, Chen W, Yao D, Oi Lam Ung C, Lai Y, Hu H. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors. Int Immunopharmacol. 2024;132:111947.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
21.  Kikuchi H, Matsui A, Morita S, Amoozgar Z, Inoue K, Ruan Z, Staiculescu D, Wong JS, Huang P, Yau T, Jain RK, Duda DG. Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma. J Natl Cancer Inst. 2022;114:1301-1305.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 54]  [Cited by in RCA: 50]  [Article Influence: 12.5]  [Reference Citation Analysis (1)]
22.  Chuang CH, Chen CT, Hsu CH, Shao YY. Carry-over effect of immunotherapy in patients with advanced hepatocellular carcinoma. Cancer Immunol Immunother. 2025;74:208.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
23.  Xie L, Liu M, Cai M, Huang W, Guo Y, Liang L, Cai W, Liu J, Liang W, Tan Y, Lai M, Lin L, Zhu K. Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma. Biomed Pharmacother. 2023;159:114254.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 20]  [Reference Citation Analysis (0)]
24.  Arai H, Battaglin F, Wang J, Lo JH, Soni S, Zhang W, Lenz HJ. Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev. 2019;81:101912.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 151]  [Cited by in RCA: 143]  [Article Influence: 20.4]  [Reference Citation Analysis (3)]
25.  Moseman JE, Rastogi I, Jeon D, McNeel DG. PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy. J Immunother Cancer. 2025;13:e011145.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 14]  [Cited by in RCA: 16]  [Article Influence: 16.0]  [Reference Citation Analysis (0)]
26.  Liu WR, Fisher DE. Epitope Spreading and the Efficacy of Immune Checkpoint Inhibition in Cancer. Int J Oncol Res. 2021;4:029.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country of origin: China

Peer-review report’s classification

Scientific quality: Grade A, Grade A, Grade B

Novelty: Grade B, Grade B, Grade B

Creativity or innovation: Grade A, Grade B, Grade B

Scientific significance: Grade B, Grade B, Grade B

P-Reviewer: Zhang S, MD, PhD, China; Zhao K, MD, Professor, China S-Editor: Liu JH L-Editor: A P-Editor: Zhao YQ

Write to the Help Desk